STOCK TITAN

Executive at NATIONAL HEALTHCARE (NHC) receives 14,000-share stock option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NATIONAL HEALTHCARE CORP reported that Senior VP & General Counsel Josh A. McCreary received a grant of stock options to purchase 14,000 shares of common stock on February 23, 2026, at an exercise price of $0.00 per share.

The options were granted under the 2020 Omnibus Equity Incentive Plan and will vest in three equal parts: one-third on February 23, 2027, one-third on February 23, 2028, and the final one-third on February 23, 2029. The grant is described as exempt from Section 16(b) under Rule 16b-3(d).

Positive

  • None.

Negative

  • None.
Insider McCreary Josh A
Role Senior VP & General Counsel
Type Security Shares Price Value
Grant/Award Option to Purchase Common Stock 14,000 $0.00 --
holding Option to Purchase Common Stock -- -- --
holding Option to Purchase Common Stock -- -- --
holding Option to Purchase Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Option to Purchase Common Stock — 14,000 shares (Direct); Common Stock — 9,942 shares (Direct)
Footnotes (1)
  1. These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on February 23, 2026. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d). These stock options will become vested and exercisable ratably over three (3) years so that one-third (1/3) will vest on February 23, 2027; one-third (1/3) will vest on February 23, 2028; and the final one-third (1/3) will vest on February 23, 2029.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McCreary Josh A

(Last) (First) (Middle)
100 VINE STREET

(Street)
MURFREESBORO TN 37130

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NATIONAL HEALTHCARE CORP [ NHC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Senior VP & General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 9,942 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock $53.94 03/08/2024 03/08/2028 Common Stock 4,000 4,000 D
Option to Purchase Common Stock $94.1 03/05/2025 03/05/2029 Common Stock 8,000 8,000 D
Option to Purchase Common Stock $90.62 02/24/2026 02/24/2030 Common Stock 13,500 13,500 D
Option to Purchase Common Stock $157.13 02/23/2026 A 14,000(1) 02/23/2027(2) 02/23/2031 Common Stock 14,000 $0 14,000 D
Explanation of Responses:
1. These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on February 23, 2026. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d).
2. These stock options will become vested and exercisable ratably over three (3) years so that one-third (1/3) will vest on February 23, 2027; one-third (1/3) will vest on February 23, 2028; and the final one-third (1/3) will vest on February 23, 2029.
/s/ Josh McCreary 02/25/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NHC report for Josh A. McCreary?

NHC reported that Senior VP & General Counsel Josh A. McCreary received a grant of options to purchase 14,000 shares of common stock. The options were granted on February 23, 2026, under the 2020 Omnibus Equity Incentive Plan at an exercise price of $0.00 per share.

How do the new NHC stock options for Josh A. McCreary vest?

The 14,000 NHC stock options granted to Josh A. McCreary vest ratably over three years. One-third vests on February 23, 2027, another third on February 23, 2028, and the final third on February 23, 2029, before becoming exercisable according to the plan terms.

Under what plan were Josh A. McCreary’s NHC options granted?

Josh A. McCreary’s options to purchase 14,000 NHC common shares were granted under the 2020 Omnibus Equity Incentive Plan. This plan provides for equity-based awards to eligible participants as part of the company’s compensation and incentive structure for executives and other key personnel.

Is the NHC option grant to Josh A. McCreary exempt from Section 16(b)?

Yes. The filing states that the grant and potential exercise of these NHC stock options are exempt from Section 16(b) under Rule 16b-3(d). This exemption generally applies to properly approved insider equity awards made under qualifying compensation arrangements.

Did the Form 4 show any open-market buying or selling of NHC common stock?

The Form 4 highlights a grant of options to purchase 14,000 NHC shares rather than open-market trades. It also lists updated holdings, including 9,942 shares of common stock held directly, but does not indicate separate buy or sell transactions in the common stock in this filing.

What is Josh A. McCreary’s role at NHC mentioned in the Form 4?

The Form 4 identifies Josh A. McCreary as Senior Vice President and General Counsel of NHC. This executive role typically covers the company’s legal affairs, governance matters, and coordination of compliance with securities regulations, including reporting of insider equity awards like this option grant.